Literatura académica sobre el tema "Tasimelteon"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Tasimelteon".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Tasimelteon"
Johnsa, Jessica D. y Michael W. Neville. "Tasimelteon". Annals of Pharmacotherapy 48, n.º 12 (9 de septiembre de 2014): 1636–41. http://dx.doi.org/10.1177/1060028014550476.
Texto completoBonacci, Janene M., Jineane V. Venci y Mona A. Gandhi. "Tasimelteon (Hetlioz™)". Journal of Pharmacy Practice 28, n.º 5 (3 de agosto de 2014): 473–78. http://dx.doi.org/10.1177/0897190014544792.
Texto completoBrooks, J., M. Gibson, K. Kite, E. Czeisler, M. Fisher, C. Xiao, C. Polymeropoulos y M. Polymeropoulos. "1161 Tasimelteon Shows Persistence Of Efficacy In Improving Sleep Disturbances In Patients With Smith-Magenis Syndrome (SMS) In Open-Label Extension Study". Sleep 43, Supplement_1 (abril de 2020): A442—A444. http://dx.doi.org/10.1093/sleep/zsaa056.1155.
Texto completoLankford, D. Alan. "Tasimelteon for insomnia". Expert Opinion on Investigational Drugs 20, n.º 7 (9 de mayo de 2011): 987–93. http://dx.doi.org/10.1517/13543784.2011.583235.
Texto completo&NA;. "Tasimelteon tackles chronic insomnia". Inpharma Weekly &NA;, n.º 1645 (julio de 2008): 5. http://dx.doi.org/10.2165/00128413-200816450-00013.
Texto completoTorres, Rosarelis, Marlene A. Dressman, William G. Kramer y Paolo Baroldi. "Absolute Bioavailability of Tasimelteon". American Journal of Therapeutics 22, n.º 5 (2015): 355–60. http://dx.doi.org/10.1097/mjt.0000000000000195.
Texto completoLi, Xi-An, Lirong Yue, Jianrong Zhu, Huazhong Ren, Hong Zhang, Dong-yan Hu, Guangtian Han, Jiafu Feng y Ze-dong Nan. "Total synthesis of Tasimelteon". Tetrahedron Letters 60, n.º 30 (julio de 2019): 1986–88. http://dx.doi.org/10.1016/j.tetlet.2019.06.048.
Texto completoDhillon, Sohita y Madeleine Clarke. "Tasimelteon: First Global Approval". Drugs 74, n.º 4 (marzo de 2014): 505–11. http://dx.doi.org/10.1007/s40265-014-0200-1.
Texto completo&NA;. "Tasimelteon helps transient insomniacs nod off". Inpharma Weekly &NA;, n.º 1667 (diciembre de 2008): 11. http://dx.doi.org/10.2165/00128413-200816670-00033.
Texto completoAdams, Katie S. y Ericka L. Breden Crouse. "Melatonin agonists in the management of sleep disorders: A focus on ramelteon and tasimelteon". Mental Health Clinician 4, n.º 2 (1 de marzo de 2014): 59–64. http://dx.doi.org/10.9740/mhc.n190087.
Texto completoTesis sobre el tema "Tasimelteon"
CIANFEROTTI, CLAUDIO. "Synthetic approaches to novel linkers for the bioconjugation of pharmaceutical active compounds". Doctoral thesis, Università di Siena, 2019. http://hdl.handle.net/11365/1071010.
Texto completoAntibody-Drug Conjugates (ADCs) are emerging as the next generation anticancer therapeutic agents. ADCs take advantage of the specificity of monoclonal antibody to target the delivery of drugs to the tumor site, with an expectation of improving the efficacy and safety of the cytotoxic payload. The linker plays a key role in the development of ADC derivatives and its blood stability as well as its possible degradation into the cell need to be carefully tuned. The synthesis of the linker offers many opportunities for organic chemistry. In this thesis we explored several different aspects of the ADC field. We developed the first ADC charged with a hydroxamic acid payload (the HDAC inhibitor vorinostat), connected through a metabolic sensitive linker. Moreover, the presence of a not highly cytotoxic drug leads to a lower systemic toxicity compared the one generally observed with traditional ADCs. With regard to self-immolative spacers, we designed a novel multifunctional branched linker that offers the opportunity of a modular synthesis of the various ADCs components. This linker is able to release a model of an amine payload from a disulfide trigger moiety. Furthermore, we present also studies towards a convergent approach to the synthesis of the linker. Besides the work on bioconjugates, we report the preparation of several synthetic impurities of the melatonin receptors agonist Tasimelteon and a new protecting group-free stereoselective synthesis of the sphingosine-1-phosphate receptor agonist Ozanimod.
Libros sobre el tema "Tasimelteon"
Blokdijk, G. J. Tasimelteon; Complete Self-Assessment Guide. CreateSpace Independent Publishing Platform, 2018.
Buscar texto completoCapítulos de libros sobre el tema "Tasimelteon"
Neubauer, David N., Ahmed S. BaHammam y Seithikurppu R. Pandi-Perumal. "Tasimelteon". En Drug Treatment of Sleep Disorders, 261–69. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-11514-6_13.
Texto completo"Tasimelteon". En What Your Patients Need to Know About Psychiatric Medications. American Psychiatric Association Publishing, 2016. http://dx.doi.org/10.1176/appi.books.9781615371280.rc14.
Texto completo"TAPENTADOL TASIMELTEON *". En Litt's Drug Eruption and Reaction Manual, 339–41. CRC Press, 2015. http://dx.doi.org/10.1201/b17996-125.
Texto completoActas de conferencias sobre el tema "Tasimelteon"
Steiger, A. "Tasimelteon reentrains sleep in a patient with phase delay syndrome". En Abstracts of the 30th Symposium of the AGNP. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1606429.
Texto completo